IGKV1-5 anticorps

N° du produit ABIN7115198

L’anticorps Lapin Polyclonal anti-IGKV1-5 a été validé pour WB et ELISA. Il convient pour détecter IGKV1-5 dans des échantillons de Humain et Souris.

Aperçu rapide pour IGKV1-5 anticorps (ABIN7115198)

Antigène: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IGKV1-5 est non-conjugé

Application: Western Blotting (WB), ELISA

Détail du produit anti-IGKV1-5 anticorps

Fonction: IGKV1-5 antibody

Purification: Immunogen affinity purified

Pureté: ≥95 % as determined by SDS-PAGE

Immunogène: immunoglobulin kappa variable 1-5

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:2000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze / thaw cycles.

Stock: -20 °C

Stockage commentaire: -20°C for 12 months

Date de péremption: 12 months

Détails sur IGKV1-5

Antigène: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Autre désignation: IGKV1-5

Sujet:

Synonyms: Immunoglobulin kappa variable 1-5|Ig kappa chain V-I region CAR|Ig kappa chain V-I region EU|Ig kappa chain V-I region HK102|Ig kappa chain V-I region Kue|IGKV1-5

Background: V segment of the variable domain of immunoglobulins light chain that participates to the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens(PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen(PubMed:20176268, PubMed:17576170).

UniProt: P01602